12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lixivaptan regulatory update

FDA's Cardiovascular and Renal Drugs Advisory Committee recommended against approval of Cornerstone's lixivaptan to treat hypervolemic hyponatremia associated with chronic heart failure (CHF) and euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH). The committee voted...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >